BRIEF published on 05/11/2026 at 08:05, 2 months 30 days ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE published on 05/11/2026 at 08:00, 2 months 30 days ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 3 months 3 days ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 3 months 3 days ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 3 months 3 days ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 4 months 10 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 4 months 10 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 4 months 10 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 4 months 22 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
BRIEF published on 03/19/2026 at 10:19, 4 months 22 days ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
Published on 08/10/2026 at 20:30, 1 hour 8 minutes ago Clean Air Metals and Fiore-backed Springbok Ventures Announce Upsize of Non-Brokered Private Placement
Published on 08/10/2026 at 15:30, 6 hours 8 minutes ago Silver Spruce Resources, Inc. Announces New Chief Financial Officer
Published on 08/10/2026 at 15:25, 6 hours 13 minutes ago Gemdale Gold Intersects 5.19m at 14.01 g/t Au within 110m at 1.18 g/t Au at the Pontio Gold Project, Finland
Published on 08/10/2026 at 14:30, 7 hours 8 minutes ago NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Published on 08/10/2026 at 13:30, 8 hours 8 minutes ago Sterling Expands High-Grade Copper Mineralization East at MEPS Intersecting 203 Metres at 0.51% CuEq: Includes 16.25 Metres at 2.31% CuEq and 9.50 Metres at 2.34% CuEq within 445 Metres at 0.40% CuEq
Published on 08/10/2026 at 20:24, 1 hour 14 minutes ago EQS-Adhoc: PNE AG updates on ongoing sales process
Published on 08/10/2026 at 19:35, 2 hours 3 minutes ago Kontron AG: All conditions of the mandatory tender offer of Ennoconn Corporation are met – Settlement will take place shortly
Published on 08/10/2026 at 19:00, 2 hours 38 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 03 AOUT 2026 au 07 AOUT 2026
Published on 08/10/2026 at 18:29, 3 hours 8 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/10/2026 at 17:50, 3 hours 48 minutes ago Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 1st Interim Report
Published on 08/10/2026 at 18:00, 3 hours 38 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 3 hours 38 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 3 hours 53 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/10/2026 at 11:53, 9 hours 44 minutes ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
